Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma ...
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study Clinical trials frequently include multiple end points that mature at ...
In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...
Pediatric patients receiving a combination of rituximab and cyclophosphamide therapy for rheumatic disease showed clinical improvement with a low risk for adverse effects. While current clinical ...
Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities. Objectives: Limited data exist on the adoption ...
FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...
Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Rituximab is comparable in terms of safety and efficacy to cyclophosphamide among patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback